Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 4 | 2023 | 346 | 1.500 |
Why?
|
| Lung Transplantation | 9 | 2016 | 175 | 1.240 |
Why?
|
| Hemangioma, Capillary | 1 | 2022 | 7 | 0.850 |
Why?
|
| Pulmonary Veno-Occlusive Disease | 1 | 2022 | 7 | 0.850 |
Why?
|
| Thromboembolism | 1 | 2022 | 119 | 0.800 |
Why?
|
| Lung Diseases | 3 | 2022 | 263 | 0.790 |
Why?
|
| Respiratory Insufficiency | 2 | 2016 | 150 | 0.730 |
Why?
|
| Epoprostenol | 1 | 2020 | 46 | 0.720 |
Why?
|
| Drug Substitution | 1 | 2020 | 25 | 0.720 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 222 | 0.690 |
Why?
|
| Multiple Chronic Conditions | 1 | 2016 | 5 | 0.580 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 521 | 0.520 |
Why?
|
| Mycobacterium avium Complex | 1 | 2015 | 6 | 0.520 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2015 | 5 | 0.520 |
Why?
|
| Macrolides | 1 | 2015 | 31 | 0.520 |
Why?
|
| Postoperative Complications | 4 | 2016 | 2207 | 0.480 |
Why?
|
| Heart-Lung Transplantation | 2 | 2017 | 17 | 0.430 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 746 | 0.350 |
Why?
|
| Quality of Life | 1 | 2016 | 1585 | 0.320 |
Why?
|
| Lung | 3 | 2022 | 1170 | 0.310 |
Why?
|
| Bronchodilator Agents | 2 | 2006 | 65 | 0.290 |
Why?
|
| Splenic Rupture | 1 | 2006 | 7 | 0.280 |
Why?
|
| Sirolimus | 3 | 2013 | 169 | 0.280 |
Why?
|
| Gastroparesis | 1 | 2006 | 14 | 0.270 |
Why?
|
| Graft Rejection | 5 | 2017 | 1065 | 0.260 |
Why?
|
| Asthma | 3 | 2019 | 955 | 0.260 |
Why?
|
| Lung Diseases, Fungal | 1 | 2003 | 17 | 0.230 |
Why?
|
| Fungemia | 1 | 2003 | 15 | 0.230 |
Why?
|
| Reproductive Health Services | 1 | 2023 | 20 | 0.230 |
Why?
|
| Opportunistic Infections | 1 | 2003 | 59 | 0.220 |
Why?
|
| Ipratropium | 1 | 2002 | 18 | 0.220 |
Why?
|
| Helium | 1 | 2002 | 10 | 0.220 |
Why?
|
| Humans | 27 | 2023 | 86653 | 0.220 |
Why?
|
| Endarterectomy | 1 | 2022 | 20 | 0.220 |
Why?
|
| Respiratory Function Tests | 1 | 2002 | 136 | 0.210 |
Why?
|
| Immunocompromised Host | 1 | 2003 | 140 | 0.210 |
Why?
|
| Tissue and Organ Procurement | 2 | 2020 | 311 | 0.210 |
Why?
|
| Immunosuppressive Agents | 3 | 2013 | 977 | 0.210 |
Why?
|
| Pulmonary Fibrosis | 1 | 2023 | 123 | 0.200 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2004 | 235 | 0.200 |
Why?
|
| Pulmonary Artery | 1 | 2022 | 306 | 0.190 |
Why?
|
| Infusions, Subcutaneous | 1 | 2020 | 3 | 0.180 |
Why?
|
| Hepatitis B | 1 | 2020 | 74 | 0.180 |
Why?
|
| Walk Test | 1 | 2020 | 21 | 0.180 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2020 | 56 | 0.180 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 394 | 0.180 |
Why?
|
| Administration, Inhalation | 1 | 2020 | 188 | 0.180 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 429 | 0.170 |
Why?
|
| Exercise Test | 1 | 2020 | 164 | 0.170 |
Why?
|
| Anticoagulants | 1 | 2022 | 408 | 0.170 |
Why?
|
| Thymoma | 1 | 2019 | 30 | 0.170 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2019 | 27 | 0.170 |
Why?
|
| Thymus Neoplasms | 1 | 2019 | 41 | 0.170 |
Why?
|
| Cytomegalovirus Infections | 2 | 2013 | 144 | 0.170 |
Why?
|
| Chronic Disease | 1 | 2022 | 971 | 0.170 |
Why?
|
| Ambulatory Care | 1 | 2020 | 181 | 0.160 |
Why?
|
| Eosinophilia | 1 | 2019 | 84 | 0.160 |
Why?
|
| Cardiac Catheterization | 1 | 2020 | 291 | 0.160 |
Why?
|
| Peptide Fragments | 1 | 2020 | 460 | 0.160 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 217 | 0.150 |
Why?
|
| Oxygen | 1 | 2002 | 726 | 0.150 |
Why?
|
| Primary Graft Dysfunction | 1 | 2017 | 27 | 0.150 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2019 | 165 | 0.150 |
Why?
|
| Stem Cells | 1 | 2019 | 351 | 0.150 |
Why?
|
| Male | 13 | 2020 | 40973 | 0.140 |
Why?
|
| Female | 15 | 2020 | 44537 | 0.130 |
Why?
|
| Consensus | 1 | 2017 | 335 | 0.130 |
Why?
|
| Epithelial Cells | 1 | 2019 | 669 | 0.130 |
Why?
|
| Transcriptome | 1 | 2019 | 580 | 0.130 |
Why?
|
| Echocardiography | 1 | 2020 | 911 | 0.130 |
Why?
|
| Middle Aged | 11 | 2020 | 25028 | 0.120 |
Why?
|
| Disease Management | 1 | 2016 | 327 | 0.120 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 1801 | 0.120 |
Why?
|
| Cells, Cultured | 1 | 2019 | 2819 | 0.120 |
Why?
|
| Societies, Medical | 1 | 2017 | 572 | 0.120 |
Why?
|
| Azathioprine | 2 | 2010 | 125 | 0.110 |
Why?
|
| Tacrolimus | 2 | 2010 | 373 | 0.110 |
Why?
|
| Bronchiolitis Obliterans | 2 | 2010 | 31 | 0.100 |
Why?
|
| Hospitals, Religious | 1 | 2010 | 29 | 0.090 |
Why?
|
| Drug Therapy, Combination | 3 | 2010 | 894 | 0.090 |
Why?
|
| Biopsy | 1 | 2013 | 1163 | 0.090 |
Why?
|
| Adult | 6 | 2020 | 25649 | 0.080 |
Why?
|
| Venous Thromboembolism | 1 | 2010 | 153 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2013 | 4213 | 0.070 |
Why?
|
| Isoproterenol | 1 | 2006 | 59 | 0.070 |
Why?
|
| Organ Transplantation | 1 | 2010 | 265 | 0.070 |
Why?
|
| Mucins | 1 | 2006 | 39 | 0.070 |
Why?
|
| Albuterol | 1 | 2006 | 35 | 0.070 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2006 | 72 | 0.070 |
Why?
|
| Gastric Emptying | 1 | 2006 | 23 | 0.070 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2006 | 17 | 0.070 |
Why?
|
| Prognosis | 2 | 2004 | 3680 | 0.070 |
Why?
|
| Primary Myelofibrosis | 1 | 2005 | 56 | 0.070 |
Why?
|
| Cytomegalovirus | 1 | 2005 | 76 | 0.060 |
Why?
|
| Decision Trees | 1 | 2004 | 63 | 0.060 |
Why?
|
| Antigens, Neoplasm | 1 | 2006 | 325 | 0.060 |
Why?
|
| Pulmonary Emphysema | 1 | 2004 | 30 | 0.060 |
Why?
|
| Macrophages, Alveolar | 1 | 2004 | 55 | 0.060 |
Why?
|
| Subclavian Artery | 1 | 2004 | 44 | 0.060 |
Why?
|
| Reperfusion Injury | 1 | 2005 | 131 | 0.060 |
Why?
|
| Pulmonary Circulation | 1 | 2004 | 86 | 0.060 |
Why?
|
| Th1 Cells | 1 | 2004 | 164 | 0.060 |
Why?
|
| Radiography | 1 | 2006 | 813 | 0.060 |
Why?
|
| Cryptococcosis | 1 | 2003 | 11 | 0.060 |
Why?
|
| Cardiomyopathies | 1 | 2006 | 240 | 0.060 |
Why?
|
| Candidiasis | 1 | 2003 | 36 | 0.060 |
Why?
|
| Aspergillosis | 1 | 2003 | 41 | 0.060 |
Why?
|
| Aerosols | 1 | 2002 | 44 | 0.060 |
Why?
|
| Antifungal Agents | 1 | 2003 | 117 | 0.050 |
Why?
|
| Telomere | 1 | 2023 | 108 | 0.050 |
Why?
|
| Leukocytes | 1 | 2023 | 202 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2002 | 399 | 0.050 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2004 | 247 | 0.050 |
Why?
|
| Carcinoma | 1 | 2005 | 436 | 0.050 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2020 | 9 | 0.050 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2020 | 24 | 0.050 |
Why?
|
| Hepatitis B Antibodies | 1 | 2020 | 15 | 0.050 |
Why?
|
| Hepatitis B virus | 1 | 2020 | 43 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 859 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2020 | 90 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 1565 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2003 | 865 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2019 | 293 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2020 | 463 | 0.040 |
Why?
|
| Incidence | 2 | 2013 | 1577 | 0.040 |
Why?
|
| Morbidity | 1 | 2017 | 148 | 0.040 |
Why?
|
| Forced Expiratory Volume | 2 | 2006 | 122 | 0.040 |
Why?
|
| Global Health | 1 | 2017 | 193 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2003 | 2262 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 2232 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2005 | 2262 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 2013 | 152 | 0.030 |
Why?
|
| Observer Variation | 1 | 2013 | 602 | 0.030 |
Why?
|
| Oklahoma | 1 | 2010 | 1 | 0.020 |
Why?
|
| Total Quality Management | 1 | 2010 | 34 | 0.020 |
Why?
|
| Models, Organizational | 1 | 2010 | 46 | 0.020 |
Why?
|
| Prednisone | 1 | 2010 | 258 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2010 | 297 | 0.020 |
Why?
|
| Continuity of Patient Care | 1 | 2010 | 169 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 860 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2010 | 280 | 0.020 |
Why?
|
| Reoperation | 1 | 2010 | 597 | 0.020 |
Why?
|
| Adolescent | 2 | 2013 | 8982 | 0.020 |
Why?
|
| Length of Stay | 1 | 2010 | 703 | 0.020 |
Why?
|
| Graft Survival | 1 | 2010 | 884 | 0.020 |
Why?
|
| Aged | 3 | 2013 | 18415 | 0.020 |
Why?
|
| Mucin-1 | 1 | 2006 | 44 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 1863 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2006 | 285 | 0.020 |
Why?
|
| Pulmonary Edema | 1 | 2005 | 50 | 0.020 |
Why?
|
| Receptors, CXCR3 | 1 | 2004 | 12 | 0.020 |
Why?
|
| Receptors, Chemokine | 1 | 2004 | 31 | 0.020 |
Why?
|
| Chemokines, CXC | 1 | 2004 | 21 | 0.020 |
Why?
|
| Chemokine CXCL10 | 1 | 2004 | 17 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2004 | 64 | 0.020 |
Why?
|
| Acute Disease | 1 | 2006 | 826 | 0.020 |
Why?
|
| Technetium Tc 99m Aggregated Albumin | 1 | 2004 | 4 | 0.020 |
Why?
|
| Heart Rate | 1 | 2006 | 492 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2004 | 220 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2004 | 180 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 6509 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2006 | 1823 | 0.010 |
Why?
|
| Time Factors | 1 | 2010 | 5210 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2006 | 1144 | 0.010 |
Why?
|
| United States | 1 | 2013 | 6674 | 0.010 |
Why?
|
| Cytokines | 1 | 2004 | 778 | 0.010 |
Why?
|
| Smoking | 1 | 2004 | 609 | 0.010 |
Why?
|
| Biomarkers | 1 | 2006 | 1718 | 0.010 |
Why?
|
| Risk Factors | 1 | 2010 | 5417 | 0.010 |
Why?
|
| Disease Progression | 1 | 2004 | 1531 | 0.010 |
Why?
|
| Animals | 1 | 2019 | 26589 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2010 | 8491 | 0.010 |
Why?
|
| Child | 1 | 2006 | 6928 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 2601 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2006 | 7993 | 0.010 |
Why?
|